Matthew P. Giannetti, MD, assistant professor, Harvard Medical School, Boston, Massachusetts, describes clonal and non-clonal mast cell activation disorders, and the relationship to the diagnosis of systemic mastocytosis. Dr Giannetti also reviews recent guideline updates that delineate the activation of mast cells as an acute event versus a chronic process.
Systemic mastocytosis, a rare blood disorder, affects the entire body. There are many challenges associated with living with this systemic mastocytosis that are centered around reducing the frequency…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
In an interview conducted at the 2025 European Society for Blood and Marrow Transplantation Annual Meeting, Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, Guy’s and St…
